Gamida Cell has announced that its Phase II/III study of StemEx for the treatment of hematological malignancies such as leukemia and lymphoma met its primary endpoint of overall survival.

StemEx is a graft of an expanded population of stem/progenitor cells, derived from part of a single unit of umbilical cord blood, and is transplanted by IV administration along with the remaining, non-manipulated cells from the same unit.

The study has enroled patients with hematologic malignancies following myleoablative therapy and who could not find a family related matched bone marrow donor.

The comparative study included the historical control cohort, which comprises a similar group of patients each transplanted with double cord blood during the years 2006-2010, according to the company.

The results demonstrated mortality of 15.8% in the StemEx group and 24.5% in the control group (p=0.034).

Gamida Cell president and CEO Dr Yael Margolin said, "We remain focused on completing the development of StemEx as an alternative stem/progenitor cell source for transplantation in patients who cannot find a family related matched bone marrow donor."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company said StemEx utilises a technology for expanding the therapeutic capacity of cord blood stem/progenitor cells for transplantation in adolescents and adults.

StemEx has been developed by the Gamida Cell-TEVA joint venture, which owns all global rights for the commercialisation of StemEx.

Gamida Cell said it is currently looking for a strategic partner for the global commercialisation of StemEx.